The Year in Biotech and What’s Ahead in 2022

Episode Summary

Executive Summary: The episode is a year-end BioReport conversation with STAT’s Adam Feuerstein reviewing biotech’s 2021 winners, losers, and major themes. He argues the year was weak for public biotech investors despite heavy capital inflows, highlights Pfizer’s execution and Biogen’s Adjahelm turmoil, and warns that preclinical IPO excess, gene therapy hurdles, and CRISPR expectations will shape 2022.

Main Topics: Biotech’s 2021 mixed year (Priority: 5/5): Feuerstein says 2021 was bad for public biotech investors even though the sector saw abundant capital and some operational progress; the year lacked a defining positive story outside COVID-related success. Worst CEO controversy and Kathy Wood’s impact (Priority: 5/5): He expands the 'worst CEO' list to 10 and singles out ARK’s Kathy Wood for fueling a genome-editing bubble by pouring large inflows into CRISPR-related names that later crashed. IPO boom and preclinical public listings (Priority: 5/5): The discussion criticizes the flood of early-stage biotech IPOs, especially preclinical companies with little fundamental support, and argues the market punishment should slow future offerings. Pfizer and Albert Bourla as the standout winner (Priority: 5/5): Bourla is praised for exceptional execution on COVID vaccines and Paxlovid, demonstrating the ability to scale manufacturing and deliver an oral antiviral in a year. Biogen’s Adjahelm fallout (Priority: 5/5): Adjahelm remains the biggest non-COVID biotech story of the year, but weak sales, price cuts, layoffs, and looming Medicare reimbursement decisions leave Biogen at a crossroads. FDA leadership and regulatory stability (Priority: 3/5): Robert Califf’s return to the FDA is viewed as likely business as usual rather than a major policy shift, with the agency still facing COVID-era operational strain. CRISPR, in vivo editing, and 2022 outlook (Priority: 4/5): Feuerstein highlights Intellia’s in vivo genome editing as a major scientific advance and expects 2022 to bring more human data across different genome-editing approaches and fresh scrutiny of gene therapy economics.

Key Arguments: Public biotech underperformed in 2021 despite large amounts of money entering the sector, showing that capital inflows do not guarantee durable value creation. Kathy Wood’s concentrated buying of genome-editing stocks helped inflate valuations beyond scientific progress, contributing to a bubble and subsequent crash. The rise of preclinical IPOs is unhealthy because companies with minimal clinical proof were going public too early and many are now trading below their offering prices. Pfizer’s year was exemplary because it converted vaccine development into massive global manufacturing output and added Paxlovid, proving strong execution can define a biotech leader. Adjahelm’s commercial weakness shows that controversial regulatory wins do not ensure market success and can trigger corporate restructuring. Robert Califf is expected to bring continuity to the FDA rather than dramatic changes, which matters for companies awaiting regulatory decisions. CRISPR should not be viewed as a single monolithic technology; the next phase will reveal which genome-editing methods work best in patients. Gene therapy must solve manufacturing, safety, reimbursement, and commercialization problems before it can become a reliable business model.

Data Points: Year referenced: 2021 - The conversation reviews biotech’s performance over the year ending December 23, 2021. Podcast recording date: December 23, 2021 - The hosts note they are recording at the end of 2021 during the pandemic and virtual JPMorgan period. Worse CEO list size: 10 - Feuerstein says he named 10 worst biopharma CEOs instead of one because it was a strong year for bad management. Genome-editing companies highlighted: 3+ companies - He cites CRISPR Therapeutics, Beam, and Editas as examples of names boosted by ARK inflows. IPO underperformance: about 70% - He says roughly 70% of biotech IPOs this year trade below their offering price. Adjahelm price cut: 50% - Biogen cut the price of Adjahelm in half due to disappointing sales. Biogen cost savings target: $500 million - The company is restructuring and aiming to save about $500 million in the next year. Medicare decision date: January 12 - A preliminary CMS reimbursement view for Adjahelm is expected on January 12. Interview horizon: 2022 - Multiple upcoming developments are framed as major watchpoints for the following year. Life science companies in Calgary: more than 110 - A sponsor segment describes Calgary’s life sciences ecosystem and company base.

Pivotal Quotes: "It was just a good year for bad CEOs. Bumper crop." — Adam Feuerstein: Explaining why he expanded his 'worst biopharma CEO' list to 10 names. "These are not – it's interesting, right? She's known as a tech investor. But, you know, when you pour a bunch of money into Google or Tesla or Apple, it's a little bit different than if you pour billions of dollars into these genome editing stocks because, you know, they're just smaller companies." — Adam Feuerstein: Describing how Kathy Wood’s inflows amplified genome-editing valuations. "The window is kind of shut or is only open to crack at this point" — Adam Feuerstein: His view that the biotech IPO market for preclinical companies has likely cooled after heavy underperformance.

Implications: Investors should be more skeptical of hype, especially in preclinical IPOs and gene-editing narratives. 2022 will likely hinge on FDA/Medicare decisions, Adjahelm’s fate, and whether CRISPR and gene therapy can translate scientific promise into real-world commercial results.